We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Human Embryonic Stem Cell Lines Now Commercially Available

By Biotechdaily staff writers
Posted on 21 May 2007
Researchers wishing to work with human embryonic stem cells (hES) now have a new commercial source of licensed, low passage cell lines.

Millipore Corp. (Billerica, MA, USA) has begun marketing two hES cell lines, MEL-1 and MEL-2. Both lines have been tested extensively with Millipore's HEScGRO media for human embryonic stem cell culture. The cell lines are provided at early passage (p10–p12), ideal for maximizing the stable lifespan of the cell line and ensuring extended research time in a stable, pluripotent state. The cells grow as well-defined colonies, with compact cells displaying high nuclear to cytoplasmic ratios and prominent nucleoli.

Millipore developed the MEL lines in collaboration with the Australian Stem Cell Centre (Clayton, Victoria) under license from the Australian National Health and Medical Research Council. A June 2006 agreement between Millipore and the Australian Stem Cell Centre allows Millipore to distribute and market these stem cell lines in all countries outside of Australia.


Related Links:
Millipore Corporation
Australian Stem Cell Centre

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Latest BioResearch News

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
21 May 2007  |   BioResearch

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
21 May 2007  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
21 May 2007  |   BioResearch